CD22 and lymphoma: Currently, six CAR-NK therapies (CD19-CAR NK, CD22-CAR NK, CD19/CD22, CD7-CAR NK,CD19-t-haNK) are assessed in clinical trials for the treatment of lymphoma patients (156).